Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on March 28, 2022. The filing discloses the launch of a syndication for new senior secured credit facilities and provides financial information related to the proposed acquisition of Héra SAS ("Héra"). The report includes unaudited pro forma financial information as of December 31, 2021, and audited financial statements for Héra for the years ended December 31, 2021 and 2020.
Key Financial Metrics and Capital Structure
The filing details the proposed structure of the New Senior Secured Credit Facilities, which are intended to finance the Héra acquisition and refinance existing debt. Specific metrics include:
- New Revolving Facility: Proposed $1,000 million five-year facility.
- New Term Loan Facilities: Proposed $300 million five-year Term Loan A and $800 million seven-year Term Loan B.
- Total Proposed Borrowing: The Company intends to borrow approximately $1,600 million, inclusive of the New Term Loan Facilities and $500 million of other unsecured debt.
- Existing Debt to be Refinanced: Includes the outstanding term loan facility and debt securities maturing in 2023.
The filing references pro forma Adjusted EBITDA and a reconciliation to pro forma loss from continuing operations in Exhibit 99.1, but does not provide specific numerical values for revenue, profit, cash flow, or margins within the text of this report. The filing text does not provide a clear value for the specific purchase price of Héra, only that proceeds will be used to finance it.
Material Changes and Transactions
The primary material change disclosed is the initiation of the syndication process for the new credit facilities. This transaction is designed to replace the Company's existing revolving facility and refinance maturing debt. The filing explicitly states that entering into the new credit facilities is not conditioned upon the consummation of the Héra acquisition, though the proceeds are intended to fund it.
Outlook, Risks, and Contingencies
Management commentary emphasizes that there can be no assurance that the syndication, refinancing, or the Héra acquisition will be consummated on the anticipated terms or at all. Significant risks and contingencies identified include:
- Transaction Risks: Failure to obtain regulatory approvals for the Héra acquisition or inability to fulfill closing conditions.
- Legal and Tax: Pending litigation regarding the restatement of previously-filed financial information and uncertain tax positions, including Notices of Proposed Assessment (NOPAs) from the U.S. Internal Revenue Service.
- Operational and Market: Impacts of the COVID-19 pandemic, supply chain disruptions, the war between Russia and Ukraine, and pricing pressures.
- Financial: Risks related to the sale of the Rx business, potential impairment charges, and fluctuations in currency and interest rates.
Investor Verification Checklist
- Verify the final terms and closing status of the $1,600 million proposed credit facilities.
- Confirm the consummation of the Héra SAS acquisition and the final purchase price.
- Review the status of the U.S. IRS tax appeals (NOPAs) and potential financial impact of adverse rulings.
- Monitor progress on the restatement litigation and any associated settlement costs.
- Assess the impact of the Russia-Ukraine conflict on the Company's supply chain and operations in affected regions.